Charles Andrew Olson

Address:

2918 12 St S, Fargo, ND 58103

VIN:

JM3ER293X70111175

Make:

MAZDA

Model:

CX-7

Year:

2007

US Patent:

6338964, Jan 15, 2002

Filed:

May 7, 1999

Appl. No.:

09/307175

Inventors:

Ricaredo Matanguihan - Walnut Creek CA
Eva Sajan - Oakland CA
Konstantin Konstantinov - Walnut Creek CA
Michael Zachariou - Walnut Creek CA
Charles Olson - Moraga CA

Assignee:

Bayer Corporation - Berkeley CA

International Classification:

C12N 500

US Classification:

435404, 435325, 435350, 435352, 435358, 435364, 435366, 435367, 435383

Abstract:

A cell culture medium which is low in dissolved carbon dioxide is disclosed. The medium contains less than about 1 g/L added sodium bicarbonate and includes an organic buffer and a metal complexing agent. The medium is preferably essentially free of added sodium bicarbonate. Methods of use of the medium in culturing mammalian cells, particularly cells engineered to produce recombinant factor VIII, are also disclosed.

US Patent:

20050003507, Jan 6, 2005

Filed:

Jun 16, 2004

Appl. No.:

10/869143

Inventors:

Paul Kostel - Richmond CA, US
Kurt Yanagimachi - Richmond CA, US
Charles Olson - Moraga CA, US

Assignee:

Onyx Pharmaceuticals, Inc. - Richmond CA

International Classification:

C12N007/02

US Classification:

435239000

Abstract:

A process for the purification of viruses from a cell lysate preparation is described, consisting of preferably two successive chromatographic steps; the first a clarification step utilizing size exclusion chromatography, and the second, a virus capture and release step using anion exchange chromatography, which successive chromatographic steps have the advantage of purifying virus, and avoiding chromatography buffer conductivity adjustments.

US Patent:

54516609, Sep 19, 1995

Filed:

Dec 13, 1993

Appl. No.:

8/166337

Inventors:

Stuart E. Builder - Belmont CA
Charles V. Olson - Pacifica CA
David Reifsnyder - San Mateo CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 3818
A61K 3830
C07K 122
C07K 14475

US Classification:

530344

Abstract:

A process is provided for selectively separating a polypeptide of interest from components of differing hydrophobicity in a mixture comprising the steps of: (a) passing the mixture through underivatized silica particles such that the polypeptide adheres to the silica particles; (b) washing the silica particles to remove impurities; and (c) eluting the polypeptide from the silica particles with a buffer comprising an alcoholic or polar aprotic solvent and an alkaline earth, an alkali metal, or an inorganic ammonium salt.

US Patent:

6214975, Apr 10, 2001

Filed:

Dec 17, 1999

Appl. No.:

9/466711

Inventors:

Michael Zachariou - Walnut Creek CA
Jonathan Mazer - Winters CA
Hyun J. Park - Los Angeles CA
Charles Olson - Moraga CA

Assignee:

Bayer Corporation - Berkeley CA

International Classification:

C07K 1700
C07K 100
C12P 2100
A61K 3514

US Classification:

530412

Abstract:

A chemiluminescence-based gel assay may be used as an indicator of fermenter health. The assay is performed using a sample of fermentation medium essentially directly from the fermenter (with no need for complicated purification of the sample before performing the assay). Results from the assay may be correlated with the final product purification yield of a given protein/purification protocol system. This may then be used as a predictor of purification yield before actually performing the purification.

US Patent:

54460247, Aug 29, 1995

Filed:

Dec 17, 1993

Appl. No.:

8/169688

Inventors:

Stuart E. Builder - Belmont CA
John R. Ogez - Redwood City CA
Charles V. Olson - Pacifica CA
David Reifsnyder - San Mateo CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 3808
C12N 1518
C07K 1400

US Classification:

514 12

Abstract:

A process for purifying IGF-I from variants of IGF-I is provided. In this process a mixture containing IGF-I and its variants is loaded onto a reversed-phase liquid chromatography column and the IGF-I is eluted from the column with a buffer at a pH of about 6-8. The buffer contains an alcoholic or polar aprotic solvent at a concentration of about 20-30% (v/v). This process can be preceded by a hydrophobic-interaction chromatography step.

US Patent:

54105560, Apr 25, 1995

Filed:

Oct 29, 1993

Appl. No.:

8/146365

Inventors:

Nan-Hsiung Yeh - Foster City CA
Charles R. Olson - Cupertino CA

Assignee:

Ampex Corporation - Redwood City CA

International Classification:

H03M 1312

US Classification:

371 43

Abstract:

A pipelined Viterbi decoder includes a plurality of circuit stages and a synchronous clocking arrangement for controlling the operations of the circuits within each stage. Specifically, an input stage converts multi-level input signals into streams of even and odd digital data samples. A parallel-precomputation stage adaptively establishes a threshold range for each sample, while a sequence detection stage designates one of the multiple levels for that sample and then determines the validity of that designation. Validity is determined in accordance with the sequence property of alternate samples in multi-level coding. Violations of the sequence property are corrected by a sequence correction stage so that valid, coded data and clock signals are provided at the outputs of the decoder.

US Patent:

54265371, Jun 20, 1995

Filed:

Jun 30, 1993

Appl. No.:

8/085196

Inventors:

Nan-Hsiung Yeh - Foster City CA
Kuo-Nan Yang - Saratoga CA
Charles R. Olson - Cupertino CA
George R. Varian - Palo Alto CA

Assignee:

Ampex Corporation - Redwood City CA

International Classification:

G11B 509

US Classification:

360 46

Abstract:

A transition overshoot of the record current is usual to compensate record head efficiency loss at high frequencies. Recording compatibility is achieved by decreasing the record current overshoot at the digital data signal transitions as the head gap depth decreases due to wear. Additionally, the different gap depth record heads of different head efficiencies require different optimum record current levels to provide maximum signal-to-noise ratio in the reproduced signal. The head gap depth thus is monitored by means of the optimum record current level without actually measuring the gap depth. The desired amount of overshoot is adaptively adjusted to the gap depth during the recording process by tracking the overshoot to the optimum record current level derived by adjusting the record drive level signal. Recording compatibility between different gap depth heads is achieved using the existing normal record current optimization process during recording.

US Patent:

20210338828, Nov 4, 2021

Filed:

Apr 20, 2021

Appl. No.:

17/235567

Inventors:

- South San Francisco CA, US
Tahir Mahmood - Burlingame CA, US
Charles Olson - South San Francisco CA, US
Weijun Feng - Danville CA, US

International Classification:

A61K 47/64
A61P 1/00
A61K 38/20

Abstract:

The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.